XB010 for Advanced Solid Tumors
Study of XB010 in Subjects With Solid Tumors
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 396 (estimated)
- Sponsor
- Exelixis · Industry
This trial is looking for adult patients with advanced solid tumors that cannot be treated with other options. Participants will receive XB010 alone or combined with another treatment called pembrolizumab to see how well it works and how safe it is.
You may be able to join if
- I am 18 years old or older.
- I have a performance status of 0-1.
- I have enough healthy organ and bone marrow function.
- I have a confirmed diagnosis of an advanced or recurrent solid tumor.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Loading trial locations…
Backup or International
650-837-7400
CONTACT